GERN: Geron Stock Surges as FDA Lifts Partial Hold on Cancer Drug

GERN stock is up over 20% Thursday afternoon.

   

GERN: Geron Stock Surges as FDA Lifts Partial Hold on Cancer Drug

Geron (GERN) shares skyrocketed after the company received some good news regarding a clinical trial for a cancer drug.

Geron 150x150 GERN: Geron Stock Surges as FDA Lifts Partial Hold on Cancer DrugThe company’s early-stage trial to test imetelstat — a myelofibrosis medication — was halted by the U.S. Food and Drug Administration in March over concerns about liver toxicity. Geron stock soared on Thursday after the FDA lifted a partial hold on the clinical trial of the drug.

The clinical trial involved 79 patients — 20 of which dropped out — and it examines how effective imetelstat is in treating the blood cancer. The company did not shed any light on why 20 patients dropped out.

Geron also started a company-sponsored clinical trial to evaluate the use of the drug in patients with thrombocythemia and multiple myeloma. The FDA also placed a hold on this trial and has not lifted it.

GERN stock is up over 20% Thursday afternoon.

More Biotech Stock News


Article printed from InvestorPlace Media, http://investorplace.com/2014/06/gern-geron/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.